US StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

MetaVia Inc

0.7437

+0.04446.35%

Volume:253.13K

Turnover:185.65K

Market Cap:18.01M

PE:-0.72

High:0.7588

Open:0.7000

Low:0.6869

Close:0.6993

52wk High:2.75

52wk Low:0.5555

Shares:24.21M

Float Shares:9.22M

Volume Ratio:0.33

T/O Rate:2.75%

Dividend:- -

Dividend Rate:- -

EPS(TTM):-1.0331

EPS(LYR):-3.5570

ROE:-168.18%

ROA:-58.41%

PB:2.84

PE(LYR):-0.21

Loading ...

Overview Company News Filings

Concept

no data

No relevant data is available

Capital Flow

Inflow:

Outflow:

News

Metavia Reports Positive Phase 2a Results for Vanoglipel in MASH Patients

Metavia Inc. Unveils Pipeline Advances Targeting Obesity and MASH

MetaVia Q3 EPS $(0.14) Beats $(0.25) Estimate

Metavia Inc. reports third quarter 2025 results and updates on clinical programs

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/MTVA"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"MTVA","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"MTVA\",,,,,undefined,":{"symbol":"MTVA","market":"US","secType":"STK","nameCN":"MetaVia Inc","latestPrice":0.7437,"timestamp":1763412339692,"preClose":0.6993,"halted":0,"volume":253131,"delay":0,"floatShares":9219300,"shares":24214788,"eps":-1.033085,"marketStatus":"Trading","change":0.0444,"latestTime":"11-17 15:48:14 EST","open":0.7,"high":0.7588,"low":0.6869,"amount":185651.61646410002,"amplitude":0.102817,"askPrice":0.7483,"askSize":100,"bidPrice":0.7412,"bidSize":100,"shortable":3,"etf":0,"ttmEps":-1.033085,"tradingStatus":2,"nextMarketStatus":{"tag":"Post-Mkt","tradingStatus":3,"beginTime":1763413200000},"marketStatusCode":2,"adr":0,"listingDate":1470369600000,"exchange":"NASDAQ","adjPreClose":0.6993,"preHourTrading":{"tag":"盘前","latestPrice":0.68,"preClose":0.6993,"latestTime":"09:15 EST","volume":1620,"amount":1115.503488,"timestamp":1763388926083},"postHourTrading":{"tag":"盘后","latestPrice":0.678,"preClose":0.6993,"latestTime":"19:58 EST","volume":7689,"amount":5225.2343,"timestamp":1763168335897},"volumeRatio":0.332146},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"MTVA\",,,,,undefined,":{"symbol":"MTVA","floatShares":9219300,"roa":"-58.41%","roe":"-168.18%","lyrEps":-3.556986,"volumeRatio":0.332146,"shares":24214788,"dividePrice":0,"high":0.7588,"amplitude":0.102817,"preClose":0.6993,"low":0.6869,"week52Low":0.5555,"pbRate":"2.84","week52High":2.75,"institutionHeld":0,"latestPrice":0.7437,"eps":-1.033085,"divideRate":0,"volume":253131,"delay":0,"ttmEps":-1.033085,"open":0.7,"prevYearClose":2.03,"prevWeekClose":0.6993,"prevMonthClose":0.9925,"prevQuarterClose":0.9402,"fiveDayClose":0.8,"twentyDayClose":1.02,"sixtyDayClose":0.65},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/MTVA\",params:#limit:5,,,undefined,":[{"market":"US","date":"2025-11-06","symbol":"MTVA","fiscalQuarterEnding":"2025/09","expectedEps":-0.26,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1762405200000,"reportTimeType":"pre","actualEps":-0.14},{"market":"US","date":"2025-08-07","symbol":"MTVA","fiscalQuarterEnding":"2025/06","expectedEps":-0.32,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1754539200000,"reportTimeType":"pre","actualEps":-0.26},{"market":"US","date":"2025-05-14","symbol":"MTVA","fiscalQuarterEnding":"2025/03","expectedEps":-0.57,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1747195200000,"reportTimeType":"post","actualEps":-0.36},{"date":"2025-03-20","symbol":"MTVA","type":"earning","reportTimeType":"pre","market":"US","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1742457600000,"name":null,"time":"Pre-Market","dateTimestamp":1742443200000,"actualEps":null},{"market":"US","date":"2024-11-07","symbol":"MTVA","fiscalQuarterEnding":"2024/09","expectedEps":-0.82,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1730955600000,"reportTimeType":"pre","actualEps":-0.55}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"MTVA\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"MTVA\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0.3333,"buy":0.6667,"hold":0,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":0.6667,"analysts":3,"updateTime":1735794000000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/MTVA\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"MTVA","date":"2025-11-14","current":-0.709041,"percent":0.179916,"low":-1.962939,"twenty":-0.895545,"median":-0.562464,"eighty":-0.481224,"high":-0.203888,"avg":-0.689147,"sd":0.34317,"marketCap":15981760},"quantilePoints":[{"date":"2024-12-06","current":-0.714557,"twenty":-0.800304,"median":-0.792227,"eighty":-0.751814,"marketCap":19816823},{"date":"2024-12-13","current":-0.716111,"twenty":-0.79347,"median":-0.728538,"eighty":-0.7158,"marketCap":19859903},{"date":"2024-12-20","current":-0.546792,"twenty":-0.767348,"median":-0.716111,"eighty":-0.685354,"marketCap":15164177},{"date":"2024-12-27","current":-0.562326,"twenty":-0.746234,"median":-0.70213,"eighty":-0.556112,"marketCap":15594978},{"date":"2025-01-03","current":-0.655529,"twenty":-0.730091,"median":-0.686597,"eighty":-0.553006,"marketCap":18179781},{"date":"2025-01-10","current":-0.661742,"twenty":-0.733198,"median":-0.686597,"eighty":-0.564811,"marketCap":18352101},{"date":"2025-01-17","current":-0.58718,"twenty":-0.720771,"median":-0.663296,"eighty":-0.577238,"marketCap":16284258},{"date":"2025-01-24","current":-0.602714,"twenty":-0.720771,"median":-0.647762,"eighty":-0.584073,"marketCap":16715059},{"date":"2025-01-31","current":-0.584073,"twenty":-0.717664,"median":-0.630675,"eighty":-0.584073,"marketCap":16198098},{"date":"2025-02-07","current":-0.562326,"twenty":-0.716111,"median":-0.615141,"eighty":-0.562326,"marketCap":15594978},{"date":"2025-02-14","current":-0.512617,"twenty":-0.714557,"median":-0.608927,"eighty":-0.546792,"marketCap":14216416},{"date":"2025-02-21","current":-0.509511,"twenty":-0.704615,"median":-0.602714,"eighty":-0.540578,"marketCap":14130256},{"date":"2025-02-28","current":-0.453589,"twenty":-0.699297,"median":-0.58718,"eighty":-0.518583,"marketCap":12579374},{"date":"2025-03-07","current":-0.487763,"twenty":-0.688995,"median":-0.584073,"eighty":-0.503297,"marketCap":13527135},{"date":"2025-03-14","current":-0.467569,"twenty":-0.681626,"median":-0.568539,"eighty":-0.495468,"marketCap":12967095},{"date":"2025-03-21","current":-0.48401,"twenty":-0.667956,"median":-0.562326,"eighty":-0.487763,"marketCap":13354815},{"date":"2025-03-28","current":-0.48933,"twenty":-0.662363,"median":-0.546792,"eighty":-0.487763,"marketCap":13501595},{"date":"2025-04-04","current":-0.47992,"twenty":-0.656772,"median":-0.540578,"eighty":-0.485083,"marketCap":13241949},{"date":"2025-04-11","current":-0.429732,"twenty":-0.643102,"median":-0.539025,"eighty":-0.482756,"marketCap":11857170},{"date":"2025-04-17","current":-0.23033,"twenty":-0.636267,"median":-0.537471,"eighty":-0.476844,"marketCap":6355270},{"date":"2025-04-25","current":-0.266622,"twenty":-0.631917,"median":-0.512617,"eighty":-0.463425,"marketCap":7356638},{"date":"2025-05-02","current":-0.239019,"twenty":-0.626947,"median":-0.506404,"eighty":-0.454331,"marketCap":6595010},{"date":"2025-05-09","current":-0.222708,"twenty":-0.618869,"median":-0.49874,"eighty":-0.452346,"marketCap":6144956},{"date":"2025-05-16","current":-0.238257,"twenty":-0.615141,"median":-0.497083,"eighty":-0.429105,"marketCap":5848960},{"date":"2025-05-23","current":-0.285534,"twenty":-0.611413,"median":-0.49458,"eighty":-0.263184,"marketCap":7009578},{"date":"2025-05-30","current":-0.543676,"twenty":-0.612655,"median":-0.49689,"eighty":-0.271352,"marketCap":13346706},{"date":"2025-06-06","current":-0.549972,"twenty":-0.608927,"median":-0.497673,"eighty":-0.281282,"marketCap":13501264},{"date":"2025-06-13","current":-0.597709,"twenty":-0.608927,"median":-0.503297,"eighty":-0.294785,"marketCap":14673160},{"date":"2025-06-20","current":-0.557862,"twenty":-0.607995,"median":-0.509511,"eighty":-0.332562,"marketCap":13694949},{"date":"2025-06-27","current":-0.542591,"twenty":-0.603956,"median":-0.515396,"eighty":-0.428478,"marketCap":13320078},{"date":"2025-07-03","current":-0.516978,"twenty":-0.602714,"median":-0.515103,"eighty":-0.429732,"marketCap":12691292},{"date":"2025-07-11","current":-0.572913,"twenty":-0.599701,"median":-0.516978,"eighty":-0.432869,"marketCap":14064436},{"date":"2025-07-18","current":-0.535431,"twenty":-0.597709,"median":-0.518414,"eighty":-0.439456,"marketCap":13144307},{"date":"2025-07-25","current":-0.587857,"twenty":-0.5965,"median":-0.521601,"eighty":-0.450482,"marketCap":14431313},{"date":"2025-08-01","current":-0.482926,"twenty":-0.587857,"median":-0.520838,"eighty":-0.453589,"marketCap":11855342},{"date":"2025-08-08","current":-0.674088,"twenty":-0.587857,"median":-0.518654,"eighty":-0.453589,"marketCap":12464564},{"date":"2025-08-15","current":-0.837521,"twenty":-0.602714,"median":-0.525504,"eighty":-0.453589,"marketCap":15486597},{"date":"2025-08-22","current":-0.836212,"twenty":-0.615141,"median":-0.534692,"eighty":-0.453589,"marketCap":15462399},{"date":"2025-08-29","current":-0.846681,"twenty":-0.624461,"median":-0.53558,"eighty":-0.454826,"marketCap":15655982},{"date":"2025-09-05","current":-0.898895,"twenty":-0.643102,"median":-0.537471,"eighty":-0.457336,"marketCap":16621475},{"date":"2025-09-12","current":-0.894708,"twenty":-0.675347,"median":-0.537746,"eighty":-0.459434,"marketCap":16544042},{"date":"2025-09-19","current":-1.200403,"twenty":-0.704615,"median":-0.540578,"eighty":-0.459802,"marketCap":22196650},{"date":"2025-09-26","current":-1.308626,"twenty":-0.720771,"median":-0.542033,"eighty":-0.464632,"marketCap":24197809},{"date":"2025-10-03","current":-1.285464,"twenty":-0.777314,"median":-0.543184,"eighty":-0.467223,"marketCap":23769507},{"date":"2025-10-10","current":-1.347885,"twenty":-0.814044,"median":-0.546792,"eighty":-0.468812,"marketCap":24923743},{"date":"2025-10-17","current":-1.360971,"twenty":-0.829721,"median":-0.548697,"eighty":-0.471608,"marketCap":25165721},{"date":"2025-10-24","current":-1.257721,"twenty":-0.836474,"median":-0.551486,"eighty":-0.475169,"marketCap":23256514},{"date":"2025-10-31","current":-1.275649,"twenty":-0.839353,"median":-0.556987,"eighty":-0.478202,"marketCap":23588024},{"date":"2025-11-07","current":-1.112332,"twenty":-0.856339,"median":-0.562326,"eighty":-0.479691,"marketCap":20568137},{"date":"2025-11-14","current":-0.985555,"twenty":-0.895545,"median":-0.562464,"eighty":-0.481224,"marketCap":15981760}],"updateTime":1763399973561},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"MTVA\",pageSize:4,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2581885386","title":"Metavia Reports Positive Phase 2a Results for Vanoglipel in MASH Patients","url":"https://stock-news.laohu8.com/highlight/detail?id=2581885386","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581885386?lang=en_us&edition=fundamental","pubTime":"2025-11-07 21:31","pubTimestamp":1762522279,"startTime":"0","endTime":"0","summary":"MetaVia Inc. has announced positive new data from its Phase 2a clinical trial evaluating vanoglipel , an oral GPR119 agonist, for the treatment of metabolic dysfunction-associated steatohepatitis . The results, which were presented at the American Association for the Study of Liver Diseases  The Liver Meeting 2025, demonstrated clinically meaningful reductions in HbA1c, improvements in liver inflammation and fibrosis, and favorable changes in plasma lipidomic profiles after 16 weeks of treatment. The data suggest vanoglipel's potential to address both hepatic and metabolic factors in MASH. The findings were shared during a poster presentation on November 10, 2025, and the poster is available on the MetaVia website.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, in","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251107:nNDL5MWT6x:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","MTVA"],"gpt_icon":0},{"id":"2581509622","title":"Metavia Inc. Unveils Pipeline Advances Targeting Obesity and MASH","url":"https://stock-news.laohu8.com/highlight/detail?id=2581509622","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581509622?lang=en_us&edition=fundamental","pubTime":"2025-11-06 21:44","pubTimestamp":1762436691,"startTime":"0","endTime":"0","summary":"Metavia Inc. has presented new clinical data on its pipeline targeting cardiometabolic diseases, including obesity and metabolic dysfunction-associated steatohepatitis . The company highlighted its lead candidate DA-1726, a novel GLP1R/GCGR dual agonist, which demonstrated weight loss of up to 6.3% and reductions in fasted glucose and waist circumference over a 26-33 day period in a Phase 1 study. The candidate was generally well-tolerated, with mild gastrointestinal events reported and no treatment-related discontinuations. Metavia also reported positive Phase 2a top-line data for Vanoglipel  in MASH, confirming primary endpoint achievement and a favorable safety profile. Additional dose-finding and longer-duration studies are ongoing. You can access the full presentation through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated conten","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251106:nNDL9qfHnV:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MTVA","BK4139"],"gpt_icon":0},{"id":"2581096148","title":"MetaVia Q3 EPS $(0.14) Beats $(0.25) Estimate","url":"https://stock-news.laohu8.com/highlight/detail?id=2581096148","media":"Benzinga","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581096148?lang=en_us&edition=fundamental","pubTime":"2025-11-06 21:41","pubTimestamp":1762436484,"startTime":"0","endTime":"0","summary":"MetaVia (NASDAQ:MTVA) reported quarterly losses of $(0.14) per share which beat the analyst consensus estimate of $(0.25) by 43.78 percent. This is a 74.55 percent increase over losses of $(0.55) per share from the same","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/25/11/48685184/metavia-q3-eps-0-14-beats-0-25-estimate","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["TSYW.SI","USJW.SI","SQQQ","TQQQ","NVIW.SI","QID","USAW.SI","MTVA","MNQmain","BK4139","NQmain","PSQ",".IXIC","QLD"],"gpt_icon":0},{"id":"2581909684","title":"Metavia Inc. reports third quarter 2025 results and updates on clinical programs","url":"https://stock-news.laohu8.com/highlight/detail?id=2581909684","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581909684?lang=en_us&edition=fundamental","pubTime":"2025-11-06 21:31","pubTimestamp":1762435912,"startTime":"0","endTime":"0","summary":"Metavia Inc. reported total other income of $0.6 million for the nine months ended September 30, 2025, down from $0.8 million for the same period in 2024, mainly due to $0.3 million in lower interest income, net, and partially offset by a $0.1 million increase in gain from the change in fair value of warrant liabilities. For the third quarter ended September 30, 2025, total other income was $0.1 million, compared to $0.6 million in the third quarter of 2024, reflecting a $0.2 million decrease in interest income and a $0.4 million change in the fair value of warrant liabilities. Cash stood at $14.3 million as of September 30, 2025, compared to $16.0 million as of December 31, 2024, with the company expecting this cash position to fund operations into 2026. During the period, Metavia dosed the first patient in the 8-week 48 mg MAD cohort of its Phase 1 clinical trial for DA-1726 in obesity, with top-line data expected by year-end 2025.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251106:nNDL7tJtJ4:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MTVA","BK4139"],"gpt_icon":0}],"pageSize":4,"totalPage":9,"pageCount":1,"totalSize":34,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/market/plate/belongs/MTVA\",params:#limit:6,delay:false,,,undefined,":[]}}